BioCentury
ARTICLE | Clinical News

MediGene reports OS data for EndoTAG-1

December 10, 2011 1:26 AM UTC

MediGene AG (Xetra:MDG) reported additional data from a Phase II trial of EndoTAG-1 to treat triple-negative breast cancer (TNBC). Once-weekly EndoTAG-1 plus paclitaxel led to a median overall survival of 13 months vs. 11.9 months for twice-weekly EndoTAG-1 monotherapy and 10.1 months for once-weekly paclitaxel monotherapy. In the per protocol (PP) population (n=124), median OS was 15.1 months for the EndoTAG-1 combination arm vs. 12.5 and 8.9 months for the EndoTAG-1 and paclitaxel monotherapy arms, respectively. MediGene said the trial was not powered for intergroup comparisons. Data were presented at the San Antonio Breast Cancer Symposium. The open-label, active-controlled, international trial enrolled 133 evaluable patients. MediGene gained EUR 0.04 to EUR 1.06 on Friday. ...